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Amyloid precursor protein (APP) is the precursor to Aβ plaques. The cytoplasmic domain
of APP mediates attachment of vesicles to molecular motors for axonal transport.
In APP-KO mice, transport of Mn2+ is decreased. In old transgenic mice expressing
mutated human (APPSwInd) linked to Familial Alzheimer’s Disease, with both expression
of APPSwInd and plaques, the rate and destination of Mn2+ axonal transport is altered,
as detected by time-lapse manganese-enhanced magnetic resonance imaging (MEMRI)
of the brain in living mice. To determine the relative contribution of expression of
APPSwInd versus plaque on transport dynamics, we developed a Tet-off system to
decouple expression of APPSwInd from plaque, and then studied hippocampal to
forebrain transport by MEMRI. Three groups of mice were compared to wild-type
(WT): Mice with plaque and APPSwInd expression; mice with plaque but suppression
of APPSwInd expression; and mice with APPSwInd suppressed from mating until 2 weeks
before imaging with no plaque. MR images were captured before at successive time
points after stereotactic injection of Mn2+ (3–5 nL) into CA3 of the hippocampus.
Mice were returned to their home cage between imaging sessions so that transport
would occur in the awake freely moving animal. Images of multiple mice from the
three groups (suppressed or expressed) together with C57/B6J WT were aligned
and processed with our automated computational pipeline, and voxel-wise statistical
parametric mapping (SPM) performed. At the conclusion of MR imaging, brains were
harvested for biochemistry or histopathology. Paired T-tests within-group between time
points (p = 0.01 FDR corrected) support the impression that both plaque alone and
APPSwInd expression alone alter transport rates and destination of Mn2+ accumulation.
Expression of APPSwInd in the absence of plaque or detectable Aβ also resulted in
transport defects as well as pathology of hippocampus and medial septum, suggesting
two sources of pathology occur in familial Alzheimer’s disease, from toxic mutant protein
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as well as plaque. Alternatively mice with plaque without APPSwInd expression resemble
the human condition of sporadic Alzheimer’s, and had better transport. Thus, these
mice with APPSwInd expression suppressed after plaque formation will be most useful in
preclinical trials.
Keywords: transgenic mice for Alzheimer’s disease investigation, amyloid precursor protein (APP), fast
microtubule-based axonal transport, CA3 of the hippocampus, dentate gyrus and septal nuclei, manganese-
enhanced magnetic resonance imaging (MEMRI), cholinergic neurons, Swedish and Indiana mutation (APPSwInd)
INTRODUCTION
Alzheimer’s disease (AD), a progressive, debilitating illness,
ends in death. No cure or even any effective treatment
is yet available. Senile plaques composed of amyloid beta
fibrils together with dystrophic neurites, and neurofibrillary
tangles of phosphorylated tau protein diagnose the disease. The
discoveries that amyloid precursor protein (APP), the parent of
amyloid beta, attaches microtubule motors to vesicular cargo
for axonal transport (Kamal et al., 2000; Satpute-Krishnan
et al., 2006; Seamster et al., 2012), and that tau protein
binds microtubules and also plays roles in transport, have
led to proposals that transport defects accompany AD, either
in causative or synergistic ways (Stokin and Goldstein, 2006;
Bearer, 2012). Projections from the hippocampus to septal and
forebrain structures are involved in cognition, and a site of
neurodegeneration in AD (Sviatko and Hangya, 2017).
We use manganese-enhanced magnetic resonance imaging
(MEMRI) to study axonal transport in the living brain (Bearer
et al., 2007a,b, 2009a,b, 2018; Zhang et al., 2010; Gallagher et al.,
2012, 2013). Manganese, a divalent metal cation, is a calcium
indicator for MRI that enters activated neurons through voltage-
gated calcium channels, secondarily enters organelles, and is
transported via microtubule motors within axons. MEMRI traces
neuronal projections from sites of stereotaxic injections and
thereby maps their connections (Pautler et al., 1998, 2003; Inoue
et al., 2011). Manganese, a paramagnetic ion, gives a strong hyper-
intense signal by T1-weighted MR (Koretsky and Silva, 2004; Silva
et al., 2004). Mn2+ is delivered by precisely localized stereotaxic
injection and the expected location of the injection site confirmed
by 0.5 h post-injection MR image, after which the mouse is
returned to its home cage. Transport then occurs in the awake
freely moving mouse and retrospectively imaged at successive
time points. After each imaging session, the mouse is returned
to its home cage (Bearer et al., 2007b, 2009a, 2018; Gallagher
et al., 2012; Medina et al., 2017a). Distal accumulation of Mn2+,
giving hyper-intense T1-weighted signal, can be identified in
MRI images using statistical parametric mapping (Friston, 1996),
revealing the anatomy of projections and rates of transport. Using
this technique, we recently reported that in aging mice expressing
a FAD-associated mutant APP, APPSwInd, and dense plaques,
transport is significantly decreased and terminal destinations are
altered (Bearer et al., 2018).
Here, we investigate whether plaques decrease transport in the
absence of mutant APP expression, or whether mutant APP on
its own, in the absence of plaque, can affect transport within the
living brain. A double transgenic mouse carrying the APPSwInd
gene under control of the Tet-off system allows separation
of plaque from APPSwInd expression (Jankowsky et al., 2005;
Bearer et al., 2018). To measure transport in the living brain,
we performed stereotaxic injections of Mn2+ into CA 3 of the
hippocampus and imaged cohorts of living mice before and at 0.5,
6, and 24 h afterward. The relative large size of the hippocampal
to basal forebrain fiber bundles renders them ideal for imaging
the progression of the Mn2+–induced hyper-intense signal at
1003 µm resolution with reasonable (∼40 min) scan times.
MATERIALS AND METHODS
Animals
To decouple the effect of mutant APP expression on transport
from the effect of amyloid-β plaque, we used transgenic mice
that overexpress a mutant human APP gene with expression
controlled by the Tet-off promoter (Jankowsky et al., 2005). The
human APP695 gene carrying both the Swedish and Indiana
mutations, each associated with Familial Alzheimer’s Disease
(FAD), was used in this study. We will refer to this gene as
“APPSwInd.” Mice with the APPSwInd mutation were deposited at
The Jackson Laboratory (JAX) (Bar Harbor, ME, United States)
by the Borchelt lab, B6.Cg-Tg(TetO-APPSwInd, strain 34845),
and were only available to us from JAX as frozen embryos. We
recovered breeding pairs and back-crossed them to C57/B6J (also
referred to as JAX strain 000664) to obtain a monogenic APPSwInd
stock congenic with C57/B6J (Bearer et al., 2018).
Monogenic tTA mice [JAX 007004B6.Cg-Tg (CamIIatTA)
1Mmay-DboJ], a transgenic line that expresses the TetO
transcription activator (tTA) in a C57/B6J background was bred
with the monogenic APPSwInd mice using IACUC-approved
breeding protocols at UNM to produce double transgenic,
TetO/APPSwInd mice. Tail snip genotyping was done by PCR
at Transnetyx to monitor the genotypes of all mice at each
generation. Four genotypes of offspring were produced with this
breeding protocol: no transgene, one or the other transgene
(monogenic tTA or monogenic APPSwInd) and double transgenic
mice (both tTA and APPSwInd). We generated 38 double
transgenic mice, both male and female, aged to 5–6 months for
our experiments. No significant difference was found between
sexes. We also analyzed data from 12 mice with a C57/B6J
background (JAX strain 000664) for a wild-type (WT) group
aged to 4–6 months acquired previously which we use as normal
controls (Gallagher et al., 2012). This is part of a multi-year
project which includes generating the monogenic APPSwInd line,
back = crossing for 10 generations in the C57/B6J strain, mating
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with tTA and aging the progeny. We began by developing
our imaging protocol, performing power analysis on pilot WT
C57/B6J mice, and comparing to other readily available mutants
that did not require aging (Gallagher et al., 2012; Medina
et al., 2017a; Bearer et al., 2018). We previously reported no
effect of monogenic APPSwInd or tTA on axonal transport of
Mn2+, hippocampal dentate width or density and numbers of
cholinergic neurons in the medial septal nuclei even at older ages
(13–15 months) (Bearer et al., 2018). Hence we did not study
these monogenics in this investigation but rather used congenic
wild type as normal controls.
Ethics Statement
All protocols involving animals in this study were approved
by Institutional Animal Care and Use Committees (IACUC) of
the California Institute of Technology and of the University
of New Mexico. Number of animals was based on our
statistical power analyses.
Tet-Off Experimental Design
Double transgenic mice were divided into three groups, which
had expression of APPSwInd switched on or off at different time
points of the life of the mice (Figure 1 and Table 1). This allowed
us to create mice that had either APPSwInd expression or amyloid-
β plaque accumulation, but not both, in two of our experimental
groups. We were thus able to observe the specific effects of each
of these two factors for the first time.
Using the Tet-off promoter, APPSwInd is normally expressed
but silenced with doxycycline (Figure 2A). Our first group,
“Group A” (+APPSwInd + Amyloid-β/plaques) (n = 11), was
never treated with doxycycline and thus expressed APPSwInd
throughout the 5–6 months of the experiment. Because of the
continuous expression of APP, these mice were expected to
accumulate amyloid-β and plaques (Bearer et al., 2018). Our
second group, “Group B” (−APPSwInd + Amyloid-β/plaques)
(n = 8), was started on doxycycline 2 weeks before the MR
images were captured and kept on doxycycline until sacrifice,
9–15 days, and histology and biochemistry studies performed.
For doxycycline, we employed Bio-Serv “Dox Diet” (200 mg/kg
doxycycline, Frenchtown, NJ, United States) to shut down
APPSwInd expression. Previous studies have shown that 2 weeks
on this diet is sufficient to decrease APPSwInd levels by >95%
(Jankowsky et al., 2005). The expected dose at 200 mg/kg of chow
for each animal was 1 mg dox per day. Chow was replenished 1–2
times per week. These mice were expected to have plaques but no
APPSwInd expression.
Our third group, “Group C” (+APPSwInd – Amyloid-
β/plaques) (n = 13), was fed the doxycycline diet via the
mother before mating (i.e., before conception) reported to reduce
APPSwInd expression by 98% (Jankowsky et al., 2005), and
then continued on doxycycline after birth until 2 weeks before
MR imaging. These mice expressed APPSwInd at the time of
experiment, but would not be expected to have amyloid-β plaque,
as APPSwInd was not expressed long enough for plaque formation
(Jankowsky et al., 2005), although a small amount of various
C-terminal fragments may be produced since the mutations
increase production of proteolytic products of APP, including
Amyloid-β (Johnston et al., 1994). The WT Group D (−
APPSwInd – Amyloid-β/plaques) (n = 12) did not carry either Tet-
off promoter or the APPSwInd gene and did not have a buildup
of amyloid-β plaque. We previously demonstrated that the
monogenic mice, either APPSwInd or tTA, were not statistically
difference from wild type even at old ages (Bearer et al., 2018).
Stereotaxic Injection
First, we collected pre-injection MR images to serve as a baseline
for alignments. Then, stereotaxic injections were performed as
described in previous publications (Bearer et al., 2007b, 2018;
Gallagher et al., 2012; Medina et al., 2017a). Briefly, mice were
anesthetized and secured in place with a stereotaxic frame
while 3–5 nL of 200 mM aqueous Mn2+ was injected into the
cornu ammonis field 3 (CA3) of the right hippocampus (target
coordinates x = 3.2 mm right of midline, y = −4.1 mm posterior
to bregma, z = 3.4 mm down from surface of brain). A quartz
micropipette guided by computer-assisted stereotaxic injector
(myNeuroLAB.com, IL, United States) was used to perform the
injection over a 5 min period. Mn2+ was used as the tract tracer
for MR imaging proposes. We choose 3–5 nL of 200 mM because
it is an amount that we previously demonstrated to be sufficient
to “saturate” the uptake system, but small enough to be non-toxic
(Gallagher et al., 2012). The volume of injectate was kept small to
enable precise placement.
The expected injection sites were confirmed by measurements
in single images taken 0.5 h after injection after alignments. The
coordinates of the center of the hypo-intense region, with the
highest concentration of Mn2+, was determined using MRIcron
(Rorden et al., 2007)1 and recorded in relation to bregma as
defined by Paxinos and Franklin atlas (Paxinos and Franklin,
2001) and plotted onto our 3D mouse brain template atlas as
previously described (Medina et al., 2017a).
Time-Lapse MR Imaging of Axonal
Transport
Mice were imaged using an 11.7 T 89 mm vertical bore Bruker
BioSpin Avance DRX500 scanner (Bruker BioSpin Inc., Billerica,
MA, United States) equipped with a Micro2.5 gradient system
equipped with a 35 mm linear birdcage radio frequency (RF)
coil. For each mouse, a pre-injection image was captured and
then images were captured at 0.5, 6, and 24 h after injection
(Figure 3). During imaging, the mice were kept under anesthesia
with 1–1.5% isoflurane. The head of each mouse was secured in
a Teflon stereotaxic unit within the RF coil to aid in reproducible
placement within the column and to minimize movement.
Respiration and temperature were monitored continuously
during data acquisition and maintained within normal ranges.
Our imaging parameters are similar to previous MEMRI studies
carried out by this group (Gallagher et al., 2012; Medina et al.,
2017a; Bearer et al., 2018). We employed a 3D multi-echo
RARE imaging sequence that is both T1- and T2-weighted, with
RARE factor of 4 and these parameters: 4 averages, TR/TE
eff = 250 ms/12 ms; matrix size of 160 × 128 × 88; FOV
16 mm × 12.8 mm × 8.8 mm; yielding 100 µm isotropic voxels
1http://people.cas.sc.edu/rorden/mricron/index.html
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FIGURE 1 | Diagram of experimental design to decouple APPSwInd expression from plaque burden. Expression of the APPSwInd gene is controlled by a
doxycycline-sensitive Tet-off promoter. Treatment with doxycycline (Dox) (green boxes), while expression of APPSwInd (blue boxes). Group A (+APPSwInd,
+Amyloid-β/plaques) (n = 11) was never treated with doxycycline. Thus Group A mice expressed APPSwInd throughout their lives and produced amyloid-β plaques
(red rising plane indicating the gradual rise in plaque accumulation). Group B (– APPSwInd, +Amyloid-β/plaques) (n = 8) was begun on doxycycline 2 weeks before
imaging. This allowed for plaque formation from the APPSwInd that was expressed throughout the life of the mice, but no APPSwInd would be expressed during the
time of experiment. Group C (+APPSwInd, –Amyloid-β/plaques) (n = 13) female mice were treated with doxycycline prior to mating and off spring continued on
doxycylcine until 2 weeks before imaging. APPSwInd was therefore expressed during the experiment but amyloid-β plaques would not be present due to the limited
amount of time in which sufficient plaque-forming APPSwInd would be expressed. Group D (–APPSwInd, –Amyloid-β/plaques) (n = 12) did not carry either the Tet-off
promoter construct or the Tet-off promoter-driven APPSwInd insert (Indicated by gray outline boxes).
with a 46 min scan duration. We identified the “scan time” as
the midpoint of the scan. No significant difference in timing
within or between groups was found. The Mn2+ intensity is
captured by T1-weighting and anatomical detail increased by T2-
weighting. No Mn2+ leakage into ventricular or vascular systems
was apparent either by visual inspection or even after statistical
comparisons within group between time points, which confirmed
no additional intensity in the ventricles over time. For time-
line of the pre-injection image, the injection and post-injection
time-lapse imaging, please refer to Figure 3.
Histology and Immunochemistry
Histology contributed to three aspects of this study: (1) To
confirm the presence or absence of plaques between Groups;
(2) To determine the histopathology of the hippocampus; and
(3) To analyze the cholinergic neurons in a target destination.
TABLE 1 | Mice.
Cohort Age Strain/numbers of animals
Group A (+APPSwInd,
+Amyloid-β/plaques)
5–6 months C57/B6J, APPSwInd/tTA
(n = 11)
Group B (−APPSwInd,
+Amyloid-β/plaques)
5–6 months C57/B6J, APPSwInd/tTA
(n = 8)
Group C (+APPSwInd,
−Amyloid-β/plaques)
5–6 months C57/B6J, APPSwInd/tTA
(n = 13)
WT Group (−APPSwInd,
−Amyloid-β/plaques)
4–6 months C57/B6J (n = 12)
Additional animals for each cohort were used for histology (see section Materials
and Methods), and some animals expired during the time course of experiments.
The mice were sacrificed after MR imaging, fixed and submitted
for histologic analysis. Histologic sections of the WT Group
from other studies performed by this lab were also included
Frontiers in Cellular Neuroscience | www.frontiersin.org 4 December 2019 | Volume 13 | Article 501
fncel-13-00501 November 29, 2019 Time: 18:24 # 5
Medina et al. Decoupling Plaques From APPSwInd Expression
FIGURE 2 | Diagram of the transgene and confirmation of doxycycline suppression. (A) In order to toggle the expression of APPSwInd, its expression was driven by a
doxycycline-sensitive Tet-off transcription factor, tTA, carried on a separate transgene under control of the neuron-specific CAMKII promoter (Mayford et al., 1996).
Whenever mice were not under doxycycline treatment, APPSwInd is expressed in neurons expressing tTA. Doxycycline treatment of double transgenic mice carrying
both transgenes inhibits the Tet-off transcription factor from binding to the Tet-Off promoter preventing it from driving APPSwInd expression. (B) Western and dot
blots of mouse brain extract from three individual mice in each group of APPSwInd mice, and Group D, WT. Note that Group A and B are positive for Aβ, and Group A
and C express APPSwInd (hAPP). SOD1 serves as a loading control that confirms amount of extract loaded in all lanes. APPSwInd (hAPP) in Group D appears similar
as Group B, suggesting the hAPP band is cross-reaction with mouse APP. (C) Examples of histologic sections from each of the four Groups, A, B. C, and D, stained
for plaque. As expected, Group A and B display classic silver-stained plaques throughout the cortex, hippocampus and some in deeper structures, such as the
thalamus, caudate-putamen and lateral geniculate. Previously we reported a few plaques in the septal regions of 6 months old APPSwInd mice (Bearer et al., 2018). In
contrast, Group C and D, as expected, have no detectible plaque.
FIGURE 3 | Imaging timeline. A pre-injection image is first captured to serve as a non-enhanced image for alignments and background subtraction of MR images for
each respective mouse. Next, 3–5 nL of Mn2+ is injected into CA3 of the hippocampus and the mouse immediately imaged by MR. After imaging, the mice are
recovered from anesthesia and returned to their home cage. MR images are captured from the same mice at 6 and 24 h after injection. Between each imaging
session, the mice are removed from the scanner, recovered from anesthesia and allowed to freely move about in their home cage. At the conclusion of the imaging
sessions, mice are sacrificed.
(Gallagher et al., 2012; Bearer et al., 2018). Subsets of these
sections were selected for microscopic analysis and examination
as specified in figure legends.
Mice were either sacrificed by cardiac perfusion of 30 ml of
warm heparinized phosphate buffer saline (PBS), followed by
30 ml of room temperature 4% paraformaldehyde (PFA) in PBS
as reported previously (Bearer et al., 2007b, 2018), or by cervical
dislocation followed by rapid brain harvest for biochemistry
(Bearer et al., 2018). Perfused mice were decapitated and then
the head rocked in 4% PFA and PBS overnight at 4◦C and
stored in PBS-azide. Each brain was released from the skull
prior to processing and fixed again for 1–3 more days. The
brains were then sent to NeuroScience Associates (Knoxville,
TN, United States) for gelatin embedding and serial sectioning
coronally in register at 35 µm thickness. Up to 25 brains
are usually embedded together in a single block. Sections are
collected in 24 sequential cups such that each cup contained
serial sections across the whole brain at approximately 840 µm
intervals. For histochemistry and immunochemistry, alternate
cups containing serial sections of 20 brains from Groups A,
B, C, and D (5 of each) were stained in a variety of ways:
Campbell-Switzer stain (Schonheit et al., 2004), a silver stain for
plaques and tangles; thionine (Nissl) for microscopic anatomy;
and immunohistochemistry for cholinergic neurons stained with
anti-ChAT antibodies (Bearer et al., 2007b, 2018) (NeuroScience
Associates, Knoxville, TN, United States).
A Zeiss V8 stereoscope was used to perform whole brain
microscopy of sections, equipped with an AxioCam running
AxioVision 4.8. For higher magnification, images were captured
on a Nikon Eclipse Ci brightfield clinical microscope with a
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DS L3 cooled digital camera. Adobe Photoshop CS 5.1 (Adobe
Systems Incorporated, San Jose, CA, United States) was used to
crop and prepare images for publication. The C57/B6J atlas was
used as reference for the position of images relative to bregma2
(Paxinos and Franklin, 2001).
Western Blots and Dot Blots
Brains were harvested within 90 s of decapitation and
plunged into liquid N2. Briefly, 10 mg of brain was first
homogenized in ice-cold Tissue-Protein Extraction Reagent (T-
PER, 78510; Pierce, now Thermo Fisher Scientific, Waltham,
MA, United States) with protease (P8340; Sigma-Aldrich) and
phosphatase (P5726; Sigma-Aldrich) inhibitor cocktails with a
Dounce homogenizer for 1 min, and then sonicated in a Bronson
sonifier set at 20% for 20 s on ice as described (Bhaskar et al.,
2010; Bearer et al., 2018). After microfuging at 14,000 rpm
in an Eppendorf microfuge for 15 min, the supernatant and
pellet are separated and stored at −80◦C. For SDS protein
gels, 20–50 µg of protein-containing extract (supernatant)
was boiled in Laemmle gel sample buffer and loaded onto a
10% SDS-PAGE for electrophoretic separation (Thermo Fisher
Scientific, Waltham, MA, United States) (Seamster et al., 2012).
Proteins were transferred to nitrocellulose in a Hoeffer tank
transfer device overnight in transfer buffer. For dot blots, 3 µl
of brain extract was dotted onto nitrocellulose and allowed
to dry for 20 min, washed in blocking buffer for 20 min,
and then probed with primary anti-Aβ monoclonal antibody
MOAB (#MABN254, Millipore, Burlington, MA, United States)
at 1:1000; or for SOD1 with polyclonal anti-SOD1, 1:1000
(#AB5482, Millipore, Burlington, MA, United States) (Bearer
et al., 2018). HRP-conjugated secondary antibodies were goat
anti-mouse (#AP308P, Millipore, Burlington, MA, United States)
and goat anti-rabbit (#AP307P, Millipore, Burlington, MA,
United States) diluted at 1:1000 in blocking buffer. Western blots
were probed with the SOD1 antibodies as a loading control,
and 6E10 anti-APP monoclonal antibody #SIG-39320 at 1:1000
(Covance, Brea, CA, United States). To compare mouse and
human APP expression, Western blots were stained in parallel
with monoclonal 22C10, or with a polyclonal rabbit antibody
raised against the conserved C-terminus of APP with pan-
species reactivity at 1:1000 (#MAB348. Millipore, Burlington,
MA, United States), and 6E10, a monoclonal against the non-
conserved N-terminus of human APP, which is non-reactive
with mouse APP, at 1:1000 (Covance, Brea, CA, United States).
Stained blots were imaged with ECL Clarity (BioRad #170-
5060, Hercules, CA, United States) on BioRad ChemiDoc XR+
using the Magic Mark ladder (Invitrogen #LC5602, Carlsbad,
CA, United States) and Kaleidoscope ladder (BioRad #161-0375,
Hercules, CA, United States). Intensity of bands was calculated
using ImageJ3.
MR Image Analysis
In order to prepare the MR images for unbiased voxel-wise
statistical analysis, several previously published processing steps
2http://www.mbl.org/atlas170/atlas170_frame.html
3https://imagej.nih.gov/ij/
must be performed on the images (Delora et al., 2016; Medina
et al., 2017b). This processing pipeline includes extracting the
brain from non-brain structures in the MR images, a process
we name “skull-stripping” (Delora et al., 2016) followed by
normalizing the intensity scale of the images and finally aligning
the images (Medina et al., 2017b). Briefly, 3D MR images
were converted to 16-bit images in the NIfTI (.nii) file format
(Neuroimaging Informatics Technology Initiative). FSL (FMRIB
software library) (Analysis Group, Oxford, United Kingdom)4
(Smith et al., 2004; Jenkinson et al., 2012) was used to check
for uniformity of header file geometry. Voxel size was uniformly
assigned using the 3drefit program from AFNI (Analysis of
Functional NeuroImages)5 (Cox, 1996; AFNI: software for
analysis). A script developed by the Jacobs lab while at California
Institute of Technology (Currently at University of Southern
California) was used to correct for B1 inhomogeneity in
MIPAV (Medical Image Processing, Analysis and Visualization)
(McAuliffe et al., 2001)6. The mode of the intensity histogram
was scaled to be equal across all images using a custom
MATLAB (MathWorks, Natick, MA, United States) script
developed by the Jacobs lab. Both of these scripts are posted
as Supplementary Material by Medina et al. (2017b). We then
generate a template mask to mask out non-brain material using
Brain Surface Extractor within BrainSuite11 followed by manual
refinement, also in BrainSuite11 (Shattuck and Leahy, 2001).
The rest of the images are skull-stripped in our automated
skull-stripper program using this template mask as a reference
image for the skull-stripper algorithm (Delora et al., 2016).
After skull-stripping, the images were then corrected again
for B-field inhomogeneity and then the grayscale normalized
again to correct for any influence non-brain material may have
had during the first normalization. The scaled images were
registered to our mouse brain template (MacKenzie-Graham
et al., 2004; Medina et al., 2017b) using our skull-stripper
program. The high resolution template living mouse brain image
what captured at 24 h post-infusion of Mn2+ systemically
at 80 µm3 voxel resolution for 4.5 h T1 scan time. This
template image can be obtained from the Current Protocols in
Molecular Biology website for our publication (Medina et al.,
2017b) which describes in more detail how our mouse brain
template was created. After alignments, including both rigid
body and non-linear procedures, the images are smoothed
with full-width half-maximum (FWHM) Gaussian kernel set to
0.3 mm using the SPM software package (Statistical Parametric
Mapping) (UCL, London, United Kingdom)7 (Friston, 1996;
Ashburner and Friston, 2001).
To create a map of Mn2+ enhancement at successive time
points as a marker of axonal transport of the Mn2+ from the
injection site, we performed SPM analysis8 following similar
methods to those we previously reported (Bearer et al., 2007b,
2018; Gallagher et al., 2012; Medina et al., 2017a). Within-group
4https://fsl.fmrib.ox.ac.uk/fsl/fslwiki/
5https://afni.nimh.nih.gov/
6https://mipav.cit.nih.gov
7http://www.fil.ion.ucl.ac.uk/spm/doc/
8http://www.fil.ion.ucl.ac.uk/spm/doc/biblio/
Frontiers in Cellular Neuroscience | www.frontiersin.org 6 December 2019 | Volume 13 | Article 501
fncel-13-00501 November 29, 2019 Time: 18:24 # 7
Medina et al. Decoupling Plaques From APPSwInd Expression
between-time-point analyses were compared using pairwise
t-tests (6 h > 0.5 h and 24 h > 0.5 h) with a p-value of 0.01 with
a false discovery rate (FDR) correction for multiple comparisons
(repeated measures) to obtain an unbiased, whole brain, voxel-
wise map of transport dynamics in SPM in all four cohorts.
Region of Interest Analysis
Volumes of 0.5 mm3 (5 × 5 × 5 voxels) were primarily selected
as regions of interest based on SPM signal observed throughout
cohorts and secondarily adjusted according to brain anatomy.
Using FSL (Analysis Group FMRIB, Oxford, United Kingdom),
selected regions were propagated across fully aligned images
specified by image coordinates, and mean intensity within each
region was calculated for each animal, at every time point.
Mean intensities for 30 m post injection images were set to 1
and the same adjustment carried through to respective animal’s
mean intensity at 6 and 24 h post injection. Statistical analyses
of ROIs were performed in GraphPad Prism using a two-
way, repeated measures ANOVA, with Bonferroni’s post hoc
test for multiple comparisons (GraphPad Software Inc, La
Jolla, CA, United States). Statistical outcomes were compiled
into a table and line graphs were created to display mean
intensity ± standard error of the mean over time within group.
Main effect of time, condition, and interaction were also analyzed
(see Supplementary Materials). Statistical significance between
groups at each time point within ROIs is indicated on the graphs
by asterisks. A 3D template image and ROIs were superimposed
in FSLeyes to create orthogonal slice images intersecting at each
ROI’s central voxel. ROI locations were determined by each ROI’s
center voxel in relation to bregma as described above.
Measurements of the Dentate Gyrus and
Stereology of ChAT Neurons of the
Medial Septal Nuclei
For the dentate gyrus, we measured the width of the granule cell
layer with the measurement tool in Fiji (Rueden et al., 2017).
We could not count cells as nuclei overlapped in these 35 µm
sections. Widths were estimated using Nissl-stained sections in
the anterior-dorsal region of the hippocampus in 2–3 sections of
five animals for each group. Both right and left hippocampi for
each animal were measured at 300 µm intervals along both arms
of the dentate, resulting in 6–9 measurements per hippocampus.
Stereology of the cholinergic neurons in the medial septal
nuclei was performed as previously described (Bearer et al.,
2018). Sections through the septal region were stained for
choline-acetyl transferase (ChAT) by immunohistochemistry
as described above. We segmented the medial septal nuclei
(MSN) in histologic sections (3 sections per mouse) based on
classical landmarks (Allen Mouse Brain Reference Atlas) (Lein
et al., 2007) and Paxinos and Franklin (Paxinos and Franklin,
2001) (also see Supplementary Material in Bearer et al., 2018).
ChAT-positive cells were counted using the Stereo Investigator
software (Microbrightfield Stero Investigator Software, Williston,
VT, United States) for design-based stereology. Area within
the contour was calculated by the stereology software. The
fractionator probe (Microbrightfield Stero Investigator Software,
Williston, VT, United States) was applied to count all ChAT-
stained cells in the MSN within a given contour, with the
anterior commissure as the landmark. Cells were only included
if the entire cell body was inside the contour. Both the number
of cholinergic neurons counted and the density of cells were
averaged for each group. The density of ChAT-sained cells was
based on the average number of neurons counted divided by the
average area occupied by the counted cells. Results were grouped
into 4 cohorts according to genotype and condition, and analyzed
with GraphPad Prism using a one-way ANOVA, and Tukey’s
post hoc tests. All stereological protocols were performed on an
Olympus DSU inverted microscope at the University of New
Mexico Fluorescence Microscopy Shared Resource Center.
RESULTS
Separation of Plaque Formation From
APPSwInd Expression
We examined five mice from each of our four groups of
tTA/APPSwInd double transgenic, Group A, Group B, Group
C, and Group D for expression of the APPSwInd transgene by
Western blot, the presence of Aβ by dot blot, and presence of
plaques by histochemistry (Figures 2B,C). As expected, Groups A
and B displayed numerous plaques, while Groups C and D had no
detectable plaques (Figure 2C). This correlated with dot blots for
Aβ (Figure 2B), which were also positive for Groups A and B and
not C and D. In contrast, also as expected by our experimental
design (Figure 1), the APPSwInd protein was detected by Western
blot in Group A and C but not Group B and D (Figure 2B). Note
that all lanes of Groups A, B and C were equivalently loaded,
as shown by the SOD1 loading control, while more extract was
loaded in Group D. Despite this higher amount, little signal
is detected for APP or Aβ. The low signal from the anti-APP
antibody in Group B and D likely represents mouse APP, which
is also expressed in these suppressible mutants, although some
signal in Group B may be the reported low amount (5%) of
APPSwInd transgene expression (Jankowsky et al., 2005).
These results confirm that Group A has both plaque and
APPSwInd expression, that Group B has plaques and little to
no APPSwInd expression, and that Group C has no plaques but
APPSwInd expression at the same level as Group A, the non-
suppressed control. We measured the intensity of bands in
Western blots probed with a pan-specific APP antibody (MAb
22C10), which recognizes both mouse and human APP, and
found that levels of transgene overexpression are approximately
3.2-fold that of mouse APP in Group A and C, as we previously
reported (Bearer et al., 2018).
Placement of the Injection Site Was
Similar for All Individual Mice in the
Study
Using MR images to locate the hypo-intense injection site 0.5 h
after injection allows us to confirm accurate placement and to
compare the position of injection across all mice (Figure 4 and
Table 2). The distance from the centroid of all injections along
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FIGURE 4 | Injection sites mapped onto a gray-scale MR image shown in transparent three-dimensions. Group A, yellow; Group B, red; Group C, blue; Group D
(WT), green (A) sagittal; (B) coronal; and (C) axial. Note the tight clustering of all injections sites in CA3 of the right hippocampus. Also see Table 2.
TABLE 2 | Actual injection site locations measured for the 30 m post-injection
MRI.
Cohort Injection sites measured in MR image 0.5 h
post-injection (mm)
X (L-R) Y (front-back) Z (deep)
Group A (+APPSwInd,
+Amyloid-β/plaques)
2.73 ± 0.37 −4.81 ± 0.21 2.42 ± 0.42
Group B (−APPSwInd,
+Amyloid-β/plaques)
3.03 ± 0.17 −4.62 ± 0.19 2.80 ± 0.26
Group C (+APPSwInd,
−Amyloid-β/plaques)
2.96 ± 0.25 −4.55 ± 0.23 2.62 ± 0.54
WT Group (−APPSwInd,
−Amyloid-β/plaques)
2.90 ± 0.32 −4.63 ± 0.30 2.43 ± 0.45
Farthest Distance from
Centroid (mm)
0.81 0.65 0.97
any particular plane was 0.97 mm or less and the overall distance
from the centroid was 1.02 mm or less. Analysis with and without
the two furthest outliers did not make a difference to the SPM
maps: the mouse that deviated 0.97 mm deep (z-plane) from
the centroid, and another that had the largest overall distance
from the centroid at 1.02 mm. Variance of all injection sites in
each of the three dimensions was 0.08 mm lateral to midline (x-
plane), 0.05 mm in the anterior-posterior direction (y-plane) and
0.17 deep (z-plane).
Gray-Scale Normalization and Image
Alignments Are Comparable Across All
Four Cohorts
Our skull stripping, normalization and alignment process
renders all images from these experiments co-equal in terms
of intensity and anatomy (Figure 5). As shown, individual
normalized aligned images are nearly indistinguishable from the
averaged image for that cohort at that time point. Since our
analysis is based on the gray-scale intensity and the anatomical
position, these processing steps are critical for interpretation. Our
normalization process aligns the mode of the intensity histogram
according to our custom MATLAB script (Medina et al., 2017b).
We validate these steps by visual inspection as well as by
quantitative comparisons of the intensity histograms before and
after normalization, and the three dimensional matrix of the
averaged and individual images.
Statistical Parametric Maps of Mn2+
Progress From Hippocampus to
Forebrain
To compare the anatomical position of statistically significant
voxels, we projected statistical maps of all four cohorts, as well
as from each cohort, onto the same gray scale image in three
dimensions at each time point (Figure 6 and Supplementary
Video S1). Coronal and sagittal slices from these 3D images
show progress of the Mn2+-induced intensity increase from the
injection site in the hippocampus along the fimbria and fornix
into the basal forebrain, known projections from CA3. The
location of the Mn2+ intensity signal depends on uptake at the
injection site in the hippocampus (Bearer et al., 2007b); axonal
transport by the anterograde kinesin-driven microtubule-based
system (Bearer et al., 2007a; Medina et al., 2017a), and possibly
the dynein-driven retrograde transport system (Matsuda et al.,
2010); APP expression (Gallagher et al., 2012) and levels of other
cargo-motor receptors; and accumulation of Mn2+ along the way
and at its distal destinations (Bearer et al., 2018). To avoid uptake
rates as possible confounders, we inject an amount of Mn2+ that
saturates uptake mechanisms (Medina et al., 2017a). However
there is the caveat that plaque in CA3 of the hippocampus may
affect uptake capacity in Groups A and B.
Visual comparisons of the four groups provide three
main observations: (1) WT (green) displays the most distal
signal at 6 h in both coronal and sagittal slices. Hence
either APPSwInd expression or plaques or both limit normal
uptake/transport/accumulation of Mn2+; (2) Only Group B (red)
with plaques but not overexpression catches up to WT at 24 h
while Group C (blue) displays limited distal accumulation and
does not appear to progress from 6 to 24 h; (3) Both Groups
with APPSwInd expression (Groups A and C) display delayed
transport, and both groups with plaques (Groups A and B)
display proximal (septal region) accumulations. We consider
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FIGURE 5 | Examples of single images and averaged images for each cohort at each time point as indicated. Note consistency between individual mice before
alignments (Sample Images) and similarities between average images (Average Images) for each time point within each of the four cohorts. Gray-scale normalization
renders all images in the same intensity scale and anatomical alignments have improved anatomical detail. Mag bar = 2.5 mm.
delayed transport as indicated by how far from the injection site
the accumulation appears.
To discover a basis for these differences, we performed three
additional analyses. Since our statistical maps are binary, and only
show whether voxels are significant above a certain threshold, we
performed region of interest (ROI) intensity measurements along
the projections across all four cohorts and three time points to
determine the actual average degree of intensity between cohorts.
To determine if alterations in the hippocampus could interfere
with uptake, we analyzed the morphology in histologic sections of
the hippocampus. And to determine if there were cellular changes
in the destination, the septum, we performed quantification of
septal areas, numbers of cholinergic cells and their density by
stereology of a subset of mice in all four cohorts.
Region of Interest (ROI) Analysis Shows
That Plaque Alters Axonal Transport, and
That APPSwInd Expression Compromises
Axonal Transport More Than Plaque
Group B represents the condition of sporadic Alzheimer’s disease,
which is not replicated in any other mouse model, as all others
constitutively express mutated proteins. Group B, in contrast,
models the condition of plaque in the absence of mutant protein
expression, as is found in human sporadic Alzheimer’s disease.
Thus for the first time, we report the effect of plaque alone
on axonal transport on the important memory circuit from
hippocampus to basal forebrain.
Intensity increased in both fimbria and lateral septum at
6 h most dramatically in Group B, with plaques but with
suppression of APPSwInd expression for 2 weeks before imaging
(Figure 7). This increase was statistically significant compared
to all other Groups, and especially significant when compared
to WT (p < 0.0001 for fimbria and <0.001 for lateral septum,
Bonferroni corrected) (see Supplementary Table S2). Thus,
plaque alone affects the dynamics of transport.
Group A, with plaques and APPSwInd expression, similar to
other mouse models of AD, had less accumulation at 6 h in
fimbria than Group B, but this intensity was still significantly
different form WT (p < 0.05, Bonferroni). Group A caught
up to WT at 24 h, as the difference was no longer statistically
significant. At 24 h, Group B sustains its statistically significant
increased signal in the fimbria (p < 0.05, Bonferroni), and in
the lateral septum (p < 0.05, Bonferroni). At 6 or 24 h in
the lateral septum, all three other cohorts are not significantly
different from WT. In contrast, at more distal locations, e.g.,
the orbital prefrontal cortex, both Groups expressing APPSwInd,
Group A with plaque and Group C without, display less intensity
suggesting delayed axonal transport at both time points. At
6 h, Group A, p < 0.01; Group C, with no plaque, p < 0.001,
Bonferroni. At 24 h these two Groups, A and C, continue to
display less intensity than WT (Group A, p < 0.05; Group C,
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FIGURE 6 | Statistical maps of each cohort. Maps are projected onto our high resolution live mouse template image (Medina et al., 2017b). All SPMs are shown at
FDR p < 0.01. To correlate anatomy of statistically significant voxels, we project all four Groups onto the same image (left column of images, A–D). (A) Coronal slices
at 6 h post Mn2+ are shown through the anterior commissure and corpus callosum for all four and for each Group separately. (B) Coronal slices at 24 h post Mn2+
injection through fornix (top), medial septum (middle) and basal forebrain (bottom). (C) Sagittal slices through the midline show progress at 6 h. Note that all three
transgenic groups display less anterior-most signal in the pre-orbital forebrain than WT. (D) Sagittal slices at 24 h show that only Group B catches up to WT, with
plaques and suppression of APPSwInd expression for 2 weeks prior to imaging. Of note is the lag in Group A, with both plaques and APPSwInd expression, and in
Group C, with no plaques and APPSwInd expression. Mag bars = 2.5 mm. Please see Supplementary Table S1 for T-values for each cohort at each time point; see
Supplementary Video S1 for 3D rendering of these maps.
p < 0.05). In contrast, Group B with plaques but no APPSwInd
expression is not significantly different from WT at either time
point in the orbital prefrontal cortex.
Lifelong Expression of APPSwInd Affects
the Dentate Gyrus of the Hippocampus
To determine whether altered transport is due to anatomical
changes in the hippocampus secondary to the timing of
APPSwInd expression or the presence of plaques, we examined
the hippocampus of the same mice imaged by MR in histologic
sections stained with thionine (Nissl) (Bearer et al., 2018)
(Figure 8). Although diminished dentate gyrus width in tTA
Tet-off mice in some strain backgrounds has been reported (Han
et al., 2012), our mice, back-crossed into the same C57/B6J
background of our APPSwInd strain, and do not display this
effect (Bearer et al., 2018). Old APPSwInd expressing mice
(13–15 months of age) had thinner dentate gyri obvious in
microscopic images and measurable by stereology, while Tet-
off monogenic mice had normal dentate gyral thickness (Bearer
et al., 2018) (Figure 8A). Group A is a younger version
of the old mice we previously reported–and at 6 months.
These mice also have decreased dentate gyrus readily visible in
histologic sections (Figure 8A) that was measurably different
(Group A, 16.7 ± 7.2 µm versus Group D, 28.1 ± 12 µm,
p < 0.0001) (Figure 8B). Group B mice, with lifelong APPSwInd
only suppressed shortly before sacrifice, displayed dentate gyrus
loss but not quite as great as Group A (19.3 ± 9 µm versus
16.7 ± 7.2 µm) although this difference is not statistically
significant. This suggests that the dentate damage may be
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FIGURE 7 | Region of interest analysis shows that expression of APPSwInd delays arrival of Mn2+- increased intensity at distal destinations, and presence of plaque
increases Mn2+ accumulation at proximal locations. Panels (A–C) shows the location on a template image in orthogonal slices of the measured 5 × 5 × 5 voxel
cube (0.5 mm3) correlating with the graphs below each set of images. In (A), coordinates in the middle of the cube are: x = –0.2, y = 0.5, z = –2.4 mm; in (B),
x = –0.7, y = –0.6, z = –3.6 mm; in (C), x = –0.3, y = –1.9, z = –2.6 mm, where x is medial-lateral from midline; y is anterior-posterior from bregma; z is dorsal-ventral
from bregma. (D–F) Graphs show intensity measures at each time point for each Group at each location as a percent change in mean intensity over time relative to
the 30 m measurement: Group A, +APPSwInd, +plaques (yellow); Group B, –APPSwInd, +plaques (red), Group C, +APPSwInd, –plaques (blue), and Group D,
–APPSwInd, –plaques (green). Error bars represent standard error of the mean. Statistical significance is indicated by asterisks from a two-way ANOVA with a
repeated measures correction (Bonferroni) for multiple comparisons between groups, with only comparisons to WT shown (∗∗∗∗P < 0.0001; ∗∗∗P < 0.001;
∗∗P < 0.01; ∗P < 0.05). Non-significant results have no asterisks. GraphPad Prism software was used to prepare graphs and perform two-way ANOVA with
repeated measures with Bonferroni correction for multiple comparisons. Mag bars = 2.5 mm. See Supplementary Table S2 for flexible factorial analysis of effects
of time, condition, and interactions as well as significance of comparisons between other groups not shown here.
FIGURE 8 | Effect of Plaque and APPSwInd on hippocampal histology. (A) Examples of thionine (Nissl) stained sections from each group as indicated. (B) Widths of
the hippocampal dentate gyrus with statistical comparisons between groups shown as quartile box plots. Means, indicated by the horizontal black line inside the
box, are: Group A, 16.7 ± 7.2 µm; Group B, 19.3 ± 9 µm; Group C, 23.5 ± 9.6 µm; Group D, 28.1 ± 12µm. Note that Group A is significantly different from C and
D. Group B is less significantly different to Group C than A suggesting it may have partially recovered from the effects of APPSwInd expression, even though this
group has plaques comparable to those in Group A, or that Group A continued to lose dentate width in the short time that APPSwInd was shut-off in Group B. Also
note in Group C that short-term expression of APPSwInd may have affected the dentate, or that there was a low APPSwInd expression during the doxycycline
treatment. The diminished dentate gyrus width is unlikely to be due to tTA expression since no such effect was observed in tTA monogenics in the C57/B6J strain
(Han et al., 2012; Bearer et al., 2018).
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recoverable if plaque formation is turned off even if plaques
remain. Group C, with expression suppressed throughout
life until just before imaging, also had some dentate loss
(23.5 ± 9.6 µm versus Group D, 28.1 ± 12 µm p < 0.001), but
less than Groups A and B.
These data show that plaque alters transport independent of
mutant protein expression, but to a lesser extent than when
together with mutant proteins. We further studied phospho-tau
deposition (Supplementary Figure S1). Clusters of mouse p-
tau aggregates were found in Groups A and B but not C, in a
distribution resembling plaques shown in Figure 2. This suggests
that p-tau aggregation is not involved in delayed transport in
Group C. Furthermore, suppression of mutant protein may
allow hippocampal recovery even if suppression does not result
in plaque resorption (Jankowsky et al., 2005). The data also
suggest that while even a short time and/or low expression of
APPSwInd does not produce plaque (see Figure 2) as in Group
C, it yet causes hippocampal changes. These results support our
interpretation of the MEMRI transport data, where in Group B
transport is more robust and dentate gyrus may be recovering
after suppression of the transgene despite pre-existing plaques.
Alternatively, expression of APPSwInd alone, without plaque, is
deleterious, since expression without plaques in Group C alters
transport, and may damage the dentate gyrus.
Effect of APPSwInd Expression Versus
Plaque on Cholinergic Neurons in the
Septum
Cholinergic neuron health depends on retrograde transport of
NGF (Tuszynski et al., 2005, 2015; Salehi et al., 2006) and also
may depend on anterograde transport from the presynaptic
neurons in the hippocampus. Cholinergic neurons of the septum
are known to become atrophic and degenerate in Alzheimer’s
disease (Sviatko and Hangya, 2017). Since these neurons are the
targets for CA3 projections, decreased Mn2+ transport from CA3
could be secondary to fewer target neurons. To determine if
APPSwInd expression and/or plaque affected the population of
septal cholinergic neurons, we stained all four of our groups by
immuno-histochemistry for choline acetyl transferase (ChAT), a
marker of cholinergic neurons (Figure 9). We determined the
number, the area and the density of ChAT neurons in each
group by stereology. The most significant decrease of ChAT
positive cells was found in Group C (Figure 9B, p < 0.0001
from WT). Group C had significantly less ChAT positive cells
than either of the other APPSwInd groups. Both the area of
the septal region measured and the density of ChAT neurons
were diminished in Group C compared to WT (p < 0.001 and
p < 0.01 respectively). Thus, loss of ChAT neurons could be
either a consequence of short term decreased transport from
hippocampus to this region, or conversely decreased ChAT
targets could be affecting transport in Group C. Since Group
C has no plaque, this effect on cholinergic neurons must be a
consequence of APPSwInd protein expression or its secondary
effects, possibly decoupled from a direct effect of transport.
Such secondary effects would include the sudden increased
production of toxic APP C-terminal fragments upon removal of
the doxycycline, lack of growth factor signaling, or paucity of
synaptic building blocks normally delivered by transport to the
presynaptic nerve terminal.
DISCUSSION
Here we show by live, longitudinal MRI of the whole brain,
differences in axonal transport dynamics with and without plaque
in mouse models of Alzheimer’s disease. The unique mouse
model created for these studies can be manipulated to have
either a high plaque burden with no mutated APP expression, or
no plaques and expression of mutated APP. By shutting down
mutant APP expression after plaques have formed, we dissociate
APP expression from plaque burden, and thereby test the effect of
each independently on transport. In all other currently available
mouse lines carrying mutant APP, expression is constitutive and
plaques develop. Hence no other system has been available to
decouple plaques from expression, which is the condition of
sporadic Alzheimer’s disease in humans. By time-lapse imaging
of the whole brain in living animals, we show for the first time the
dynamics of axonal transport in the central nervous system, and
how FAD proteins impact this physiologic process. Furthermore,
by quantitative examination of hippocampal morphology and
cell counts in the basal forebrain cholinergic system, we begin
to dissect the impact of transport dynamics on neuronal health.
A next step will be to learn how these transport dynamics
affect cognition.
Our results support previous ideas that mutated APP is toxic,
independent of plaque (Gunawardena and Goldstein, 2001, 2004;
Rodrigues et al., 2012; Weissmiller et al., 2015; Xu et al., 2016).
We show in live imaging of the whole brain that expression of
APPSwInd in the absence of plaque decreases axonal transport
from hippocampus to basal forebrain, and affects the number of
cholinergic neurons in the septum. While plaque also has an effect
on transport success, this effect it is much less than the expression
of mutated APP, and has been invisible in mouse models with
constitutive mutant protein expression.
Why might this be? Our mutated APP contains two mutations
that increase gamma secretase activity and are dominant
mutations in human families, the Swedish double mutation
(Thordardottir and Graff, 2018) and the Indiana single amino
acid substitution (Murrell et al., 1991). Hence inheritance of one
copy of this gene results in 100% penetrant Alzheimer’s disease–
the mutation poisons endogenous APP. Our mice have normal
mouse APP and a 3.2-fold expression of this poisonous mutated
protein. Our results predict that expression of mutated APP,
independent of plaque, diminishes nourishing axonal transport
to critical distal targets–septal region of the basal forebrain–
and may have other, non-transport-related toxic effects. This
diminished transport together with toxic APPSwInd is deleterious
for cholinergic neurons, and likely other distal target cells
not witnessed here.
This does not mean that aggregation of Aβ into plaque has
no consequences. Plaque also caused pathology, although less
dramatic in assays of axonal transport, and cholinergic neuron
number. Plaque alone did not result in decreased transport in
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FIGURE 9 | Effects of APPSwInd expression and plaque on basal forebrain cholinergic neurons. (A) Example of the medial septal region containing cholinergic
neurons, stained for ChAT (brown) and outlined in the stereology set-up used for measurement (blue line). (B–D) Box and whisker plots showing quartile distributions
of the number of ChAT positive cells, the area in the outlined septal region, and the density of cells (counts/area) in each of the four groups, as labeled. ∗p < 0.01;
∗∗p < 0.001, ∗∗∗p < 0.0001 as indicated.
these mice. But plaque decreased the width–i.e., the number of
cells–in the dentate gyrus, indicating either cell death or lack of
neuronal renewal, which occurs through stem cell division in that
region of the mouse brain and likely in human as well.
How might we be wrong in our interpretation of these
imaging and histology results? Differences in the injection
site placement were minimal, and thus unlikely to account
for the differences in transport observed between groups.
Perhaps the mutated protein changes Mn2+ uptake through
neuronal calcium channels. However, APP FAD mutations
do not affect calcium signaling (Stieren et al., 2010). Hence
this seems a less likely reason. Increased expression of
APP itself, even without a mutation, might reduce axonal
transport and damage cholinergic neurons. This explanation
is also unlikely, since in our peer-reviewed publication on
Down Syndrome, also performed with MEMRI, we found
increased transport with 1.5-fold expression of APP, a gene
on the triplicated chromosome, and decreased numbers of
cholinergic neurons in the basal forebrain (Bearer et al.,
2007b). Plaque may also affect uptake in the hippocampus,
although the data from Group B, with better transport than
A despite hippocampal plaques, argues against that possibility.
Furthermore, decreased transport in Group C, with no plaque,
suggests that plaque-related uptake differences are not a major
factor in our results.
Others have also reported that this APP mutation causes
transport defects in cell culture systems, where transport is
imaged as particle movements rather than intensity changes
(Rodrigues et al., 2012). Transport defects may occur through
cleavage of the cytoplasmic domain of APP by gamma secretase,
which removes the kinesin-binding domain that mediates cargo
motility (Kamal et al., 2000, 2001; Satpute-Krishnan et al., 2006).
Such cleavage would also produce a soluble cytoplasmic domain
that would bind kinesin and inhibit it from associating with
other organelles. Hence not only would the APP-containing
vesicles lose transport capability, but other organelles would
have to compete with the cytoplasmic fragment to acquire
motors. We have shown that soluble peptides derived from
the cytoplasmic domain of APP when injected into the squid
axon inhibit transport (Satpute-Krishnan et al., 2006; Bearer and
Wu, 2019) through binding to kinesin (Seamster et al., 2012).
Primary hippocampal cultures or slices from the mice used in this
study could be implemented to tease apart the consequences of
APPSwInd expression and plaque on transport of specific cargoes.
Since our Down Syndrome findings were with a small (1.5-
fold) increased expression of normal APP, which in mouse
does not produce plaques, the possibility remains that increased
protein concentration due to the 3.2-fold excess expression in
our APPSwInd transgenic mouse may non-specifically inhibit
transport. Indeed, many disorders of cognition involve protein
aggregates that likely represent an abnormally high level of
protein in the cytoplasm. How cognition depends on transport
will be an important area of future study. It will be interesting to
know if other cognitive disorders share a transport defect, since
the biological basis of cognition remains a mystery. What is the
role of axonal transport in this critical human mental process?
Currently it is unclear whether transport deficits cause
pathology or vice versa, and ever present question in the
field of axonal transport research. Here we aimed to address
this but found that in our 6-month old mice, even those
with suppressed APPSwInd expression, there was both transport
defects and pathology, with decreased ChAT neurons and
dentate width. Future experiments in younger mice may identify
an age in which the hippocampus and ChAT neurons are
not yet impacted in the disease models, but the transport
phenotype is present. Such a finding would provide stronger
evidence for the importance of transport deficits to the (possibly)
subsequent pathology. Alternatively, lifelong expression of
APPSwInd may have deleterious effects that we have not studied
here. Alternatively, if, as results suggest, suppressing APPSwInd
expression results in some recovery despite the continued
presence of plaque, future experiments with a longer period of
suppression could be valuable.
Finally, we may consider how this new information might
lead to therapeutic interventions. If suppression of Amyloid-β
production results in dentate and ChAT neuronal recovery as our
results with Group B suggest, then targeting peptide production
rather than plaques may have significant therapeutic potential.
Since the dentate represents a region of active neurogenesis,
the impact of toxic APP fragments may interfere with this
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process in addition to promoting death of mature neurons.
Recent developments using vaccine-based approaches to
both tauopathies (Maphis et al., 2019) and APP-related
disorders (Chackerian et al., 2006; Chackerian, 2010;
Li et al., 2010) may provide vehicles for such new
treatments aimed at suppressing toxic proteins. We might
also ask if transport can be restored, and if so, does
cognition improve?
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